HER2/neu testing in gastric cancer by immunohistochemistry: Assessment of interlaboratory variation

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 11, 2014, Pages 1495-1502

  Sheffield, Brandon S ^a   Garratt, John ^a,b   Kalloger, Steve E ^c   Li Chang, Hector H ^c   Torlakovic, Emina E ^b,d   Gilks, C Blake ^a,b   Schaeffer, David F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Canadian Immunohistochemistry Quality Control (CIQC)   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; EVALUATION STUDY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OBSERVER VARIATION; PROCEDURES; PROTO ONCOGENE; STATISTICS AND NUMERICAL DATA; STOMACH NEOPLASMS; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORIES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OBSERVER VARIATION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84923879022     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0604-OA     Document Type: Article

References (21)

1. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230-236.
2. American Cancer society. Stomach cancer detailed guide: stomach cancer survival rates. http://www.cancer.org/cancer/stomachcancer/. Accessed November 11, 2013.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20.
4. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
5. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19(1):554-568.
6. Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol . 2002;10(3):234-241.
7. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-697.
8. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
9. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-650.
10. Asioli S, Maletta F, Verdun di Cantogno L, et al. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. Hum Pathol. 2012;43(11):2070-2079.
11. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) Histopathology. 2011;58(3):383-394.
12. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjustment trial. J Clin Oncol. 2006;24(19):3032-3038.
13. Choritz H, Busche G, Kreipe H; Study Group HER2 Monitor. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011;459(3):283-289.
14. Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 testing study (GaTHER): An evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 2012;36(4):577-582.
15. Terry J, Torlakovic EE, Garratt J, et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian quality control immunohistochemistry (cIQc) and Canadian association of pathologists (CAP) national standards committee/immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009;17(5):375-382.
16. Dekker TJ, Borg S, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14(3):R93. doi:10.1186/bcr3208.
17. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21(10):1271-1277.
18. Fassan M, Ludwig K, Castoro C, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 2012;43(8):1206-1212.
19. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of HER2/neu in primary lesions is responsible for the discordant HER2/neu status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59(5):822-831.
20. Wolff AC, Hammond ME, Schwartz JN, et al American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
21. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neuimmunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011;136(5):754-761.